In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
about
Current and emerging azole antifungal agentsIn vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogensIn vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and CandidaAntifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemiaIn vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformansInteractions of posaconazole and flucytosine against Cryptococcus neoformansEvaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida speciesSynergy of nitric oxide and azoles against Candida species in vitro.Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeastsComparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformansActivity of SCH 56592 compared with those of fluconazole and itraconazole against Candida sppActivity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiaeDetection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologiesIn vitro activity of a new polyene, SPA-S-843, against yeasts.Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus sppInteractions between triazoles and amphotericin B against Cryptococcus neoformans.In vitro and in vivo activities of posaconazole against Coccidioides immitis.In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesMutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.In vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis.In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.Activity of posaconazole in treatment of experimental disseminated zygomycosis.Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.Advances in synthetic approach to and antifungal activity of triazoles.
P2860
Q24550733-C77FE721-0D12-4421-8C84-DD062639A1A4Q28343832-D468E14E-2086-4E7A-8D25-9B74C19B4EE2Q28344464-7F8F4480-15A5-4393-B2EB-105847F2ADC2Q28349552-399C9B5D-FEE7-4CE4-9514-1ACFDCEBEA04Q28353303-0CB9149A-5222-4558-A197-E526C612A500Q28362562-A4473893-3C21-4873-B402-34689A87ECE3Q28362760-C8DCE65D-9D58-48BC-99A8-89AE7EF86330Q28368892-02D30620-6279-4AD7-9C4B-3578761D00AAQ28368930-4D8160AC-D2AE-45F4-96B8-ECAE6C90D599Q28379123-5277E880-8D27-4350-B19E-B7C68BE438EAQ28379177-C7E315E1-056A-4159-A42A-EDDCC200BB0BQ28379453-5801F1C1-6974-47C7-B53D-E4E13EA43330Q33677651-8D2A5BB9-F814-4411-9920-87E9ECC0DCB3Q33702041-89ED8EF5-D9C4-4F03-A95F-23A15627236BQ33753016-7A9B8393-0695-4196-9056-E375ED468A27Q33980497-32EE0B34-255C-485D-9605-7E0433D6D69BQ34107135-220F1199-043C-4CB1-9EC3-61C42684B9F0Q34452652-B668DF1D-D30B-4461-8368-8D9A3CE4447AQ34823914-CD2F1CF7-B68E-4EE3-9DD7-CE90CDDB9277Q35077994-BE763BBE-3A32-431F-9171-1A2F68AF0D0DQ35136173-F0653740-8075-4A03-BE0E-EC39FB90C9CFQ36880761-0AD98AC3-14AF-4640-A582-E09B98BFD8FFQ37568516-F3229131-B5A1-4013-904F-B6E35FB41016Q39651554-A4273320-624F-448C-A5F1-90F51C19B35AQ42206400-4BE4619C-A4FB-409A-A1C4-1E50205D387F
P2860
In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
In vitro studies of activities ...... s, and other pathogenic yeasts
@ast
In vitro studies of activities ...... s, and other pathogenic yeasts
@en
In vitro studies of activities ...... s, and other pathogenic yeasts
@nl
type
label
In vitro studies of activities ...... s, and other pathogenic yeasts
@ast
In vitro studies of activities ...... s, and other pathogenic yeasts
@en
In vitro studies of activities ...... s, and other pathogenic yeasts
@nl
prefLabel
In vitro studies of activities ...... s, and other pathogenic yeasts
@ast
In vitro studies of activities ...... s, and other pathogenic yeasts
@en
In vitro studies of activities ...... s, and other pathogenic yeasts
@nl
P2860
P1476
In vitro studies of activities ...... s, and other pathogenic yeasts
@en
P2093
J N Galgiani
P2860
P407
P577
1997-01-01T00:00:00Z